<DOC>
	<DOC>NCT00567840</DOC>
	<brief_summary>The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 200, 600, 1000 and 1200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive tuberculosis. A control group will receive standard TB treatment.</brief_summary>
	<brief_title>PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Pulmonary</mesh_term>
	<criteria>informed consent M/F 1864 yo newly diagnosed pulmonary TB sputum positive adequate contraception poor health rifampicin resistance treatment with other anti TB agents in last 3 mos. extrapulmonary TB COPD neuropathy ECG wih QRS prolongation ove 120 msec CV disorder diabetes requiring insulin Metabolic disease drug/alcohol abuse pregnancy use of substances that are strong inhibitors/inducers of CYP450 use of ARV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Early Bactericidal Activity</keyword>
	<keyword>EBA</keyword>
	<keyword>pulmonary tuberculosis</keyword>
	<keyword>PA-824</keyword>
	<keyword>Pretomanid</keyword>
	<keyword>CL-007</keyword>
</DOC>